SCHEMBL680700

SCHEMBL680700

Cc1ccc(-c2cc3c(cnn3C3CCCCO3)cc2O)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.52
RXRB P28702 1/20 0.52
RXRG P48443 1/20 0.52
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
ATR Q13535 5/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
HSD17B10 Q99714 1/20 0.36
POLQ O75417 1/20 0.35
ABL1 P00519 1/20 0.35
GSK3B P49841 2/20 0.34
DYRK1A Q13627 2/20 0.34
WNT1 P04628 1/20 0.34
MTOR P42345 1/20 0.34
JUN P05412 2/20 0.34
MAPK10 P53779 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680848 0.86 RXRA (0.53) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680219 0.82 RXRA (0.50) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29000796 0.82 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL30380061 0.82 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL20437571 0.79 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL23976083 0.79 RXRA (0.50) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL680965 0.77 RXRA (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL28693246 0.77 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL29470669 0.76 CYP4F2 (0.49) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL20439390 0.75 RXRA (0.51) RXRARXRBRXRGCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC RXRA 4592/4885RXRB 4066/4885RXRG 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.